CliffBio
small molecule

DEPODUR

MORPHINE SULFATE

Loss of exclusivity—loss of exclusivity
CompanyPacira Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEPODUR
Active ingredientMORPHINE SULFATE
Strength15MG/1.5ML (10MG/ML)
Dosage formINJECTABLE, LIPOSOMAL
RouteEPIDURAL
ModalitySmall molecule
FDA approvalMay 2004
Marketing statusDISCN

More from Pacira Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DEPODUR patent cliff — loss of exclusivity — | CliffBio